Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis


News provided by

Eli Lilly and Company

16 Jun, 2017, 05:00 GMT

Share this article

Share toX

Share this article

Share toX

BASINGSTOKE, England, June 16, 2017 /PRNewswire/ --

Through interactive data visualization, RA Matters allows the RA community to see and compare the results of the survey in real time: http://ramatters.eu/

Eli Lilly and Company (NYSE: LLY) today announced the results of the RA Matters survey. The results showed regardless of characteristic or country, that the understanding of rheumatoid arthritis (RA), its symptoms and how RA makes people feel, has a large impact on people's lives.

The RA Matters survey uncovered that despite major advances in the treatment of RA, physical symptoms such as fatigue (43%) and pain (39%), continue to be the biggest barriers for people with RA in the workplace.[1] Difficulty using their hands was the biggest challenge to people carrying out work. Daily activities are also impacted by the disease, with more than 60 percent[1] of people with RA finding it significantly hinders their ability to exercise and 23 percent[1] of people with RA reporting that they have problems with daily routines such as washing and personal care. Despite much progress in addressing the physical burden of RA, many people feel RA hinders their ambitions for the future. Over 50 percent of the respondents with RA hope for a better understanding from others of the physical impact that RA has on their lives.[1]

"The RA Matters survey shone a light on people living with RA and shows how our understanding of RA and how it makes people feel remains a major barrier to improving the lives of those living with this disease," said Roberto Servi, Senior Director & International Therapeutic Area Leader - Europe at Eli Lilly and Company. "The hope is that RA Matters will add crucial patient perspectives and mark a step change in engaging people with RA about what matters most to them in their daily lives. We hope these survey findings will contribute to ensuring the standard of care for this community is improved further."

"RA can often be unpredictable. Some people experience long periods of disease inactivity then flare unexpectedly, whilst others have highly active disease with symptoms on a daily basis lasting for months at a time. These fluctuations can often lead to feelings of distress, lack of control, isolation and may limit people's hopes for the future," said Clare Jacklin, Director of External Affairs, NRAS, UK. "The RA Matters survey has provided a platform for people living with RA to voice what really matters to them. Life with RA should not be a compromise. It should be about taking control of this debilitating disease and not having your life defined by it."

People living with RA also bear an emotional burden that can make them compromise on some of the most fundamental aspects of life. The RA Matters survey revealed that the level of understanding and empathy from those around them can also have an effect on people's behaviours and emotions, with 44 percent of people with RA reporting a negative impact on their relationship with their spouse or partner.[1] A lack of understanding from colleagues about the physical and emotional burden of RA was reported as a major professional barrier, with 43 percent of people with RA reporting that they felt their jobs were not flexible enough for their circumstances.[1]

"The RA Matters survey demonstrates the true physical and emotional burden of life with RA and can help us to identify the most important personal goals for individuals with the disease," said Prof. Dr. med. Rieke Alten, Head of Department of Internal Medicine II - Rheumatology, Schlosspark-Klinik Berlin(Germany). "More must be done to ensure relevant treatment and management decisions also include what matters most to those with RA. Only by better identifying and integrating such perspectives, can we hope to improve RA outcomes further."

RA is a systemic autoimmune disease[2] affecting more than 23 million people worldwide.[3] In many countries, people with RA have a high prevalence of co-morbidities[4] and it is well established that RA negatively affects health-related quality of life.[5] The RA Matters survey was developed with the support of RA patient groups, advocates and physicians from across Europe and Canada. 6,208 participants took part across eight countries, including 5,400 people living with RA and 808 healthcare professionals (rheumatologists, physicians and nurses), revealing what matters most to them in terms of activities, work, personal relationships and aspirations.

About Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune disease characterised by inflammation and progressive destruction of joints.[6] More than 23 million people worldwide suffer from RA.[3] Approximately three times as many women as men have the disease.[7]

About RA Matters

6,208 people participated in the RA Matters survey, of which 5,400 were people who had been diagnosed with RA, and 808 were rheumatologists or healthcare professionals (HCPs) that treat RA. The survey was carried out between November 4, 2016 and February 13, 2017, from eight participating countries (Canada, France, Germany, Italy, Netherlands, Spain, Sweden and the United Kingdom). The RA Matters survey set out to fill a gap in the existing RA evidence base. The over-arching objective of the survey was to demonstrate the real unmet need in RA. Specifically the survey explored the outcomes and quality of life related areas that are most important, relevant and impactful of patients' lives.

Using an innovative visual data collection method on a live web platform, the RA Matters survey allowed people to see and compare their results in real time - helping us to bring important RA stories to life. For more information on the RA Matters survey and to explore the findings, please visit http://ramatters.eu/; http://ramatters.ca].

The RA Matters survey was supported and/or informed by the following individuals and organisations:

  • Arthritis Consumer Experts (Canada)
  • The Arthritis Society, Canada (Canada)
  • Canadian Arthritis Patient Alliance (Canada)
  • AFPric (France)
  • ANDAR (France)
  • ANMAR (Italy)
  • ConArtritis (Spain)
  • Sociedad Española de Reumatología (Spain)
  • National Rheumatoid Arthritis Society (UK)

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at http://www.lilly.co.uk.

(P-LLY)

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's product pipeline and reflects Lilly's current beliefs. However, there are substantial risks and uncertainties in the process of pharmaceutical research, development, and commercialization. For further discussion of these and other risks and uncertainties, see Lilly's most recent 10-K and 10-Q filings with the United States Securities and Exchange Commission. Except as may be required by law, Lilly undertakes no duty to update forward-looking statements for events occurring after the date of this release.

References 

1. Data on File RA Matters questionnaire REF 31954, REF 31955, REF 31956 2017 

2. American College of Rheumatology, Rheumatoid Arthritis, http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp (Accessed: May 4, 2017)

3. World Health Organisation (WHO). The Global Burden of Disease Report, (table 7, page 32) 2004, http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (Accessed: May 4, 2017)

4. Dougados M, Soubrier M, Antunez A. et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014; 73: 62 - 68

5. Strand V et al. Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. J Rheumatol 2015;42;2046-2054. http://www.jrheum.org/content/42/11/2046

6. Kahlenberg J and Fox D. Advances in the Medical Treatment of Rheumatoid Arthritis. Hand Clinics 2011 February ; 27(1): 11-20. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135413/pdf/nihms305780.pdf (Accessed: May 4, 2017)

7. Arthritis Foundation. What is Rheumatoid Arthritis? http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php (Accessed: May 4, 2017)

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.